## Georgia ADAP Prior Approval Application Hepatitis C Medications

DATE OF REQUEST:				
CLIENT INFORMATION:				
Client Name (Last, First, M):				
District/Clinic where the client is seen:				
Client/Caregiver:				
1) Patient is willing to take (or caregiver to administer) medications as directed.   Yes  No				
2) Patient has prior evidence of adherence to therapy and medical care; and prescriber has reasonable expectation that adherent behavior will continue.				
3) Patient's home has sufficient storage at the proper temperature.   Yes  No				
DRUGS REQUESTED & REQUIRED INFORMATION:				
Please complete the sections below by checking the appropriate boxes, and supplying the requested responses/supporting documentation.				
Please select requested regimen from the options listed below:  ☐ Harvoni <sup>TM</sup> (Ledipasvir 90mg/ Sofosbuvir 400mg)  ☐ Epclusa <sup>TM</sup> (Velpatasvir 100mg/ Sofosbuvir 400mg)  ☐ Zepatier <sup>TM</sup> (Elbasvir 50mg/ Grazoprevir 100mg)  ☐ Mavyret <sup>TM</sup> (Glecaprevir 100mg/ Pibrentasvir 40mg)  ☐ Other regimen. Please specify:  ☐ Requesting the State Medical Advisor to make treatment recommendation.				
Requested Course of Therapy: 8 weeks (only Mavyret), 12 weeks, 16 weeks				
1) Client is an active and stable ADAP client. ( <i>Requirement</i> )				
2) Client Weight: 3) Client Age: 4) Client Sex:				
5) Current antiretroviral regimen:				
6) List of current non-HIV medications:				
7) Does the client have a history of the following?				
Allergies				
- What medications?				
- Describe the reaction:				

Edited 7/2023 Page 1 of 3

## Georgia ADAP Prior Approval Application Hepatitis C Medications

☐ Intolerances					
- What medications?					
L					
- Describe the reaction:					
0\ 71	. 04 04 11 1				
	opies of the following lab work:				
- Conducted in the past two (2) months:					
CMP (including albumin, bilirubin, ALT, AST)					
□ CBC					
□ PT/INR					
- Conducted at any time prior to starting therapy:					
☐ HIV Viral Load					
CD4 Count					
☐ Hepatitis A (HAV) Total Antibody					
☐ Hepatitis C (HCV) A	Antibody				
☐ HCV Viral Load					
☐ HCV Genotype/Subtype					
☐ HBV Coinfection: HBsAg, anti-HBs, and anti-HBc					
☐ If prior HCV treatme	ent, incude HCV genotypic resistance to	est.			
- Conducted before starting therapy:					
Pregnancy Test (if w	voman of childbearing age)				
- If available:					
Liver Biopsy Results	S				
☐ FibroSure					
☐ FibroScan					
☐ Enhanced Liver Fibr	osis Test				
Recent right upper q	uadrant ultrasound or computer tomogr	raphy of abdomen ar	nd pelvis		
9) Does the client have cirrho	osis?		☐ Yes ☐ No		
- If yes, which stage?		☐ compensated	decompensated		
10) Does the client have a hist	cory of Hepatitis C treatment?		☐ Yes ☐ No		
- If yes, what treatment?					
- Length of treatment?					
- Outcome of treatment?					

Edited 7/2023 Page 2 of 3

## Georgia ADAP Prior Approval Application Hepatitis C Medications

**NOTE:** Providers must submit results of the test of cure Hepatitis C Viral Load at treatment culmination and again at 12-weeks following treatment completion.

Prescriber Information:				
Provider Name (Last, First, M):		Phone:		
Email:	Signature:			
Please provide details for the <b>administering provider</b> if different from the prescribing provider. The administering provider will be contacted for follow up <b>12 weeks</b> after treatment completion to document cure/failure/non-adherence, etc.				
Provider Name (Last, First, M):		Phone:		
Email:				
Clinical Request Determination:				
Date Received:	Date of Decision:	:		
Request approved Request Denied				
Medical Advisor (Last, First, M):				
Phone: Email	1:			
Medical Advisor/ Prescriber Signature:				
Comments/Additional Information or Instructions:				
Provider/Prescriber Guidelines:				
Patient must have a repeat HIV viral load within 2-8 weeks from medication initiation and If the HIV RNA is				
detectable at 2-8 weeks, repeat testing every 4-8 weeks until viral load is suppressed to <200 copies/mL.  If CD4 and/or viral load have not improved, clinical improvement (or clinically stable if condition was				
worsening before) must be documented for continuation of the new regimen.				
The prescriber must review the state guidelines and/or restrictions concerning the use of these medications to determine that the patient qualifies.				
The prescriber should be an experienced HIV/AIDS provider or should consult with a specialist and must have sufficient office/clinic capability to provide patient education and monitoring.				
Guidelines: https://clinicalinfo.hiv.gov/en/guidelines				
Hepatitis C Guidelines: <a href="http://www.hcvguidelines.org/">http://www.hcvguidelines.org/</a>				
Georgia Department of Public Health Hepatitis C Testing Toolkit				

Edited 7/2023 Page 3 of 3